News | July 10, 2024
Lilly to acquire Morphic to improve outcomes for patients with inflammatory bowel disease
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
Currently, Sharma is a part of the Philippines Country Leadership Team as Business Unit Head Respiratory & Immunology
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Subscribe To Our Newsletter & Stay Updated
